Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05191472 · MORE INFO

Limitations, agreements, and source contact

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies · Source last updated 2025-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study closed earlier than expected due to slow accrual
point Of Contact
email
Alfred.Chung@ucsf.edu
organization
University of California, San Francisco
phone
(415) 476-1000
title
Dr. Alfred Chung, MD
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study closed earlier than expected due to slow accrual
point Of Contact
email
Alfred.Chung@ucsf.edu
organization
University of California, San Francisco
phone
(415) 476-1000
title
Dr. Alfred Chung, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice